Passion for Innovation.
Compassion for Patients.™

Daiichi-Sankyo

# Daiichi Sankyo ESMO Follow-up Meeting Hosted by Citi

September 24, 2020

# Forward-Looking Statements

Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo's future prospects. These forward looking statements were determined by Daiichi Sankyo based on information obtained as of today with certain assumptions, premises and future forecasts, and thus, there are various inherent risks as well as uncertainties involved. As such, please note that actual results of Daiichi Sankyo may diverge materially from Daiichi Sankyo's outlook or the content of this material. Furthermore, there is no assurance that any forward-looking statements in this material will be realized. Regardless of the actual results or facts, Daiichi Sankyo is not obliged and does not have in its policy the duty to update the content of this material from the date of this material onward.

Compounds under discussion are investigational agents and are not approved by the FDA or any other regulatory agency worldwide as a treatment for indications under investigation. Efficacy and safety have not been established in areas under investigation. There are no guarantee that these compounds will become commercially available in indications under investigation.

Daiichi Sankyo takes reasonable care to ensure the accuracy of the content of this material, but shall not be obliged to guarantee the absolute accuracy, appropriateness, completeness and feasibility, etc. of the information described in this material. Furthermore, any information regarding companies, organizations or any other matters outside the Daiichi Sankyo Group that is described within this material has been compiled or cited using publicly available information or other information, and Daiichi Sankyo has not performed in-house inspection of the accuracy, appropriateness, completeness and feasibility, etc. of such information, and does not guarantee the accuracy thereof.

The information described in this material may be changed hereafter without notice. Accordingly, this material or the information described herein should be used at your own judgment, together with any other information you may otherwise obtain.

This material does not constitute a solicitation of application to acquire or an offer to sell any security in the United States, Japan or elsewhere.

This material disclosed here is for reference purposes only. Final investment decisions should be made at your own discretion.

Daiichi Sankyo assumes no responsibility for any damages resulting from the use of this material or its content, including without limitation damages related to the use of erroneous information.

1 U3-1402 Ph1 NSCLC

2 DS-8201 DESTINY-Gastric01
HER2 Low Cohorts

3 Q&A



Passion for Innovation.
Compassion for Patients.™

Daiichi-Sankyo

# Efficacy and Safety of Patritumab Deruxtecan (U3-1402), a Novel HER3 Directed Antibody Drug Conjugate, in Patients With EGFR-Mutated NSCLC

Helena A. Yu, MD
Memorial Sloan Kettering Cancer Center
New York, NY, USA

Helena A. Yu, Christina Baik, Kathryn Gold, Hidetoshi Hayashi, Melissa L. Johnson, Marianna Koczywas, Haruyasu Murakami, Makoto Nishio, Conor Steuer, Wu-Chou Su, James C. H. Yang, Samer Karam, Zhenhao Qi, Yang Qiu, Shuquan Chen, Channing Yu, and Pasi A. Jänne

Co-author affiliations are listed in the abstract.
This study is sponsored by Daiichi Sankyo, Inc.
Presentation LBA62.

# Phase 1 Study of Patritumab Deruxtecan (U3-1402), a HER3 Directed Antibody Drug Conjugate, in EGFR-mutated NSCLC

HER3 is expressed in most lung cancers, (~80% of *EGFR*-mutated NSCLC), overexpression is associated with worsened clinical outcomes[1]

**Patritumab Deruxtecan (U3-1402)**

A novel HER3 directed antibody drug conjugate composed of the monoclonal antibody patritumab, a tetrapeptide-based linker, and a topoisomerase I inhibitor payload




***Dose Escalation***[a]

*Metastatic/unresectable **EGFR-mutated NSCLC** either after progression on osimertinib or T790M-negative after progression on erlotinib, gefitinib, or afatinib*

*Patritumab deruxtecan 5.6 mg/kg Q3W*
**n = 12**

**Dose Expansion Cohort 1**[b]

Metastatic/unresectable ***EGFR*-mutated NSCLC** and treatment with ≥ 1 EGFR TKI and ≥ 1 prior platinum-based chemotherapy regimen

Patritumab deruxtecan 5.6 mg/kg Q3W
**n = 45**

**Primary Objective:** Antitumor activity of patritumab deruxtecan

**Secondary Objectives:** Safety and tolerability of patritumab deruxtecan

- Stable brain metastases were allowed
- Pretreatment tumor tissue (after progression on TKIs) required for retrospective analysis of HER3 expression
- As of 4/30/20, 57 patients from dose escalation and dose expansion had been treated with 5.6 mg/kg patritumab deruxtecan
- 56 patients were evaluable for response (1 patient did not have any evaluable post-baseline tumor assessments)
- 6 patients had only 1 tumor evaluation

**A phase 1 study of patritumab deruxtecan in NSCLC (NCT03260491). Safety and activity in patients with *EGFR*-mutated NSCLC treated with 5.6 mg/kg patritumab deruxtecan. Data cutoff April 30, 2020.**

1. Tan CS, et al. *Mol Cancer*. 2018;17(1):29.

[a]Patients in dose escalation had NSCLC (adenocarcinoma) and received 3.2 mg/kg-6.4 mg/kg of patritumab deruxtecan, which was guided by mCRM following EWOC principle.

[b]Patients in dose expansion were enrolled into 3 cohorts; **data for patients with NSCLC (adenocarcinoma) enrolled in Cohort 1 are included in this analysis**. Patients with squamous or nonsquamous NSCLC without *EGFR* activating mutations will enroll into Cohort 2. Patients with *EGFR*-mutated NSCLC adenocarcinoma (including any histology other than combined cell and non-small cell) will be randomized 1:1 to receive 5.6 mg/kg or aRDE (Cohort 3a) or an up-titration of patritumab deruxtecan (Cohort 3b).

# Characteristics, Disposition, and Exposure in Patients Treated With 5.6 mg/kg Patritumab Deruxtecan

- Median follow-up was 5 months (range, 0-15 months)
- Median treatment duration was 3.5 months (range, 1-14 months)

| Baseline Demographics and Disease Characteristics | N = 57 |
|---|---|
| **Median age (range), years** | 65 (40-80) |
| **Female, n (%)** | 36 (63) |
| **Race, n (%)** | |
| Asian | 27 (47) |
| White | 25 (44) |
| African American | 2 (4) |
| Other | 3 (5) |
| **ECOG PS, n (%)** | |
| 0 | 23 (40) |
| 1 | 34 (60) |
| **Median number of therapies for advanced/metastatic disease (range)** | 4 (1-9) |
| **Prior therapy, n (%)** | |
| EGFR TKI | 57 (100) |
| Osimertinib | 49 (86) |
| Other EGFR targeted therapy | 3 (5) |
| Platinum-based chemotherapy | 51 (90) |
| Anti-PD-1/PD-L1 | 23 (40) |
| **History of CNS metastases** | 27 (47) |

| Disposition | N = 57 |
|---|---|
| **Ongoing on study treatment** | 28 (49) |
| **Discontinued study** | 29 (51) |
| Progressive disease | 13 (23) |
| Clinical progression | 5 (9) |
| Adverse event | 5 (9) |
| Consent withdrawal | 3 (5) |
| Investigator decision | 1 (2) |
| Death | 2 (3) |
| **HER3 expression** | |
| **Evaluable patients, n** | 43 |
| **Median membrane H score (range)** | 180 (2-280) |




A phase 1 study of patritumab deruxtecan in NSCLC (NCT03260491). Safety and activity in patients with *EGFR*-mutated NSCLC treated with 5.6 mg/kg patritumab deruxtecan. Data cutoff April 30, 2020.

# Patritumab Deruxtecan 5.6 mg/kg Demonstrated Antitumor Activity In EGFR-mutated NSCLC With Diverse TKI Resistance Mechanisms







**A phase 1 study of patritumab deruxtecan in NSCLC (NCT03260491). Safety and activity in patients with *EGFR*-mutated NSCLC treated with 5.6 mg/kg patritumab deruxtecan. Data cutoff April 30, 2020.**

[a]This analysis does not include 7 patients without post-baseline tumor assessments by the data cutoff date.

[b]Performed centrally using Oncomine™ Comprehensive Assay v3 from pretreatment tumor tissue. Results from local testing are included for patients where tissue was unavailable for central analysis. Additional mutations detected from cfDNA in blood collected prior to treatment with U3-1402 using GuardantOMNI™ assay are included. For cfDNA analysis, a minor allelic frequency of 1% was used as a threshold for detection of mutations. The copy number data from cfDNA are not shown.

# Antitumor Response Occurs Within 3 Months in Patients Treated With 5.6 mg/kg Patritumab Deruxtecan

| Activity according to BICR evaluation (efficacy-evaluable population) N = 56[a] | |
|---|---|
| **Confirmed BOR, n/N (%)** | |
| CR | 1/56 (2%) |
| PR | 13/56 (23%) |
| SD | 25/56 (45%) |
| PD | 9/56 (16%) |
| NE | 8/56 (14%) |
| **Confirmed ORR, % (n/N; 95% CI)** | 25% (14/56; 14.4-38.4) |
| **DCR, % (n/N; 95% CI)** | 70% (39/56; 55.9-81.2) |
| **Median TTR, months (range)** | 2.0 (1.2-2.8) |
| **Median DoR, months (range)** | 6.9 (3.0-7.0) |







**A phase 1 study of patritumab deruxtecan in NSCLC (NCT03260491). Safety and activity in patients with *EGFR*-mutated NSCLC treated with 5.6 mg/kg patritumab deruxtecan. Data cutoff April 30, 2020.**

[a]Of 56 patients, 22 (39%) had best percentage decrease in sum of tumor diameters ≥ 30%. [b]This analysis does not include 7 patients without post-baseline tumor assessments by the data cutoff date.

# Safety Summary of Patients Treated With 5.6 mg/kg Patritumab Deruxtecan

- Patritumab deruxtecan continued to demonstrate a manageable safety profile
  - The most common grade ≥3 TEAEs were thrombocytopenia (16 patients [28%]) and neutropenia (11 patients [19%])
  - TEAEs associated with discontinuation (9%) included fatigue (n = 2), decreased apetite (n = 1), ILD (n = 1), pneumonitis (n = 1), and URTI (n = 1)
    - There were no discontinuations due to thrombocytopenia or neutropenia
  - Three (5.3%) ILD events were adjudicated by an independent central review committee as being related to treatment
  - There were no treatment-related TEAEs associated with death

| TEAEs (regardless of causality), n (%) | N = 57 |
|---|---|
| **TEAEs** | 57 (100) |
| Grade ≥3 | 38 (67) |
| Associated with discontinuation | 5 (9) |
| Associated with dose reduction | 10 (18) |
| Associated with dose interruption | 17 (30) |
| Associated with death | 3 (5) |
| **Treatment-emergent SAEs** | 21 (37) |
| Grade ≥3 | 18 (32) |
| Treatment related | 11 (19) |

| TEAEs in ≥20% of patients, n (%) | N = 57 | |
|---|---|---|
| | All grades | Grade ≥3 |
| **Fatigue** | 33 (58) | 5 (9) |
| **Nausea** | 31 (54) | 2 (4) |
| **Thrombocytopenia[a]** | 30 (53) | 16 (28) |
| **Decreased appetite** | 20 (35) | 1 (2) |
| **Neutropenia[b]** | 19 (33) | 11 (19) |
| **Vomiting** | 17 (30) | 1 (2) |
| **Alopecia** | 17 (30) | NA |
| **Anemia[c]** | 15 (26) | 5 (9) |
| **Constipation** | 14 (25) | 0 |

**A phase 1 study of patritumab deruxtecan in NSCLC (NCT03260491). Safety and activity in patients with *EGFR*-mutated NSCLC treated with 5.6 mg/kg patritumab deruxtecan. Data cutoff April 30, 2020.**

[a]Thrombocytopenia includes decreased platelet count and thrombocytopenia. [b]Neutropenia includes decreased neutrophil count and neutropenia. [c]Anemia includes decreased hemoglobin, decreased red blood cell count, anemia, and decreased hematocrit.

# Phase 1 Study of Patritumab Deruxtecan (U3-1402) in *EGFR*-mutated NSCLC: Conclusions

- Patritumab deruxtecan, a HER3 directed ADC, continued to demonstrate a **manageable safety profile** and **clinically meaningful antitumor activity at 5.6 mg/kg** (the recommended dose for expansion)
- Early antitumor activity was observed in this heavily pretreated patient population, with a median follow-up time of 5 months
  - 28 patients are ongoing treatment
  - 3 PRs are not yet confirmed
  - 6 patients had only 1 tumor evaluation
- Activity was observed in patients without and with **diverse mechanisms of TKI resistance**, including *EGFR* C797S mutation, *MET* amplification, *HER2* mutation, *BRAF* fusion, and *PIK3CA* mutation
- These data support further clinical investigation of this HER3 directed ADC in a patient population with no available targeted therapy treatments
  - A **phase 2 study** of single-agent patritumab deruxtecan in patients after failure of EGFR TKIs and platinum-based chemotherapy therapy is planned

**A phase 1 study of patritumab deruxtecan in NSCLC (NCT03260491). Safety and activity in patients with *EGFR*-mutated NSCLC treated with 5.6 mg/kg patritumab deruxtecan. Data cutoff April 30, 2020.**

Passion for Innovation.
Compassion for Patients.™

Daiichi-Sankyo

# Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: results of the exploratory cohorts in the phase 2, multicenter, open-label DESTINY-Gastric01 study

Kensei Yamaguchi, MD
The Cancer Institute Hospital of JFCR, Tokyo, Japan
On behalf of the DESTINY-Gastric01 investigators

# DESTINY-Gastric01

An open-label, multicenter, randomized, phase 2 study

T-DXd is an antibody-drug conjugate consisting of an anti-HER2 antibody, cleavable tetrapeptide-based linker, and topoisomerase I inhibitor payload

In the DESTINY-Gastric01 (NCT03329690) primary cohort[1] of 187 patients with HER2-positive gastric or GEJ cancer previously treated with trastuzumab, T-DXd 6.4 mg/kg compared with standard chemotherapy demonstrated:

- A significantly higher ORR (51.3% vs 14.3%) and greater confirmed ORR (42.9% vs 12.5%)
- Longer OS (median, 12.5 vs 8.4 months)
- Improved mPFS (5.6 vs 3.5 months)

Here, we present results for the exploratory cohorts of DESTINY-Gastric01

1. Shitara K, et al. *N Engl J Med*. 2020;382:2419-2430.

# DESTINY-Gastric01

## An open-label, multicenter, randomized, phase 2 study




- All patients received T-DXd 6.4 mg/kg q3w
  - Cohort 1 IHC 2+/ISH− (n = 20); cohort 2 IHC 1+ (n = 24)
- Patients had not previously received anti-HER2 treatment
- Median of 2 prior lines of therapy for advanced/metastatic disease
  - 18% had irinotecan, 84% had ramucirumab, 32% had anti–PD-1/PD-L1
- At data cutoff (8 November 2019), no patients in cohort 1 and 2 in cohort 2 (8.3%) remained on treatment

# Primary Endpoint: ORR

## DESTINY-Gastric Exploratory Cohort

| | Primary Cohort[1] | | Exploratory Cohorts | |
|---|---|---|---|---|
| | **T-DXd (n = 119)** | **PC Overall (n = 56)** | **Cohort 1 IHC 2+/ISH− (n = 19)** | **Cohort 2 IHC 1+ (n = 21)** |
| **ORR by ICR (CR + PR)** | **51.3% (n = 61)** **95% CI, 41.9-60.5; *P* < .0001[a]** | **14.3% (n = 8)** **95% CI, 6.4-26.2** | **36.8% (n = 7)** **95% CI, 16.3%-61.6%** | **19.0% (n = 4)** **95% CI, 5.4%-41.9%** |
| **Confirmed ORR by ICR (CR + PR)** | **42.9% (n = 51)** **95% CI, 33.8-52.3** | **12.5% (n = 7)** 95% CI, 5.2-24.1 | **26.3% (n = 5)** **95% CI, 9.1%-51.2%** | **9.5% (n = 2)** **95% CI, 1.2%-30.4%** |
| CR | 8.4% (n = 10) | 0 | 0 | 0 |
| PR | 34.5% (n = 41) | 12.5% (n = 7) | 26.3% (n = 5) | 9.5% (n = 2) |
| SD | 42.9% (n = 51) | 50.0% (n = 28) | 63.2% (n = 12) | 61.9% (n = 13) |
| PD | 11.8% (n = 14) | 30.4% (n = 17) | 10.5% (n = 2) | 28.6% (n = 6) |
| NE | 2.5% (n = 3) | 7.1% (n = 4) | 0 | 0 |
| **Confirmed DCR (CR + PR + SD)** | 85.7% (n = 102) 95% CI, 78.1-91.5 | 62.5% (n = 35) 95% CI, 48.5-75.1 | 89.5% (n = 17) 95% CI, 66.9%-98.7% | 71.4% (n = 15) 95% CI, 47.8%-88.7% |
| **Median confirmed DOR** | 11.3 months 95% CI, 5.6 months-NE | 3.9 months 95% CI, 3.0-4.9 months | 7.6 months 95% CI, 4.1 months-NE | 12.5 months 95% CI, NE-NE |

Includes data for the response-evaluable set: all randomized (for primary cohort) patients who received ≥ 1 dose of study drug and had measurable tumors based on independent central review at baseline.

[a]Comparison between T-DXd and PC overall using Cochran-Mantel-Haenszel test stratified by region.

1. Shitara K, et al. *N Engl J Med*. 2020;382:2419-2430.

# Best Percentage Change From Baseline in Tumor Size

## DESTINY-Gastric Exploratory Cohort







The line at 20% indicates progressive disease; line at −30% indicates partial response. Includes patients in both cohorts who had both baseline and postbaseline target lesion assessments by independent central review. One patient in each cohort was excluded due to no baseline measurable disease by ICR. Three additional patients in the IHC 1+ cohort were excluded due to no postbaseline assessment (n = 1) or a missing HER2 status by central laboratory (n = 2).

# Overall and Progression-Free Survival

## DESTINY-Gastric Exploratory Cohort

### Overall Survival




### Progression-Free Survival




[a] Two patients were excluded from analysis due to a missing HER2 status by central laboratory.

# Safety Summary

## DESTINY-Gastric Exploratory Cohort

| Adverse Events (≥ 20% in either cohort) | Cohort 1 IHC 2+/ISH− (n = 20) | | Cohort 2 IHC 1+ (n = 24) | |
|---|---|---|---|---|
| Preferred Term, n (%) | Any Grade | Grade ≥ 3 | Any Grade | Grade ≥ 3 |
| Decreased appetite | 65 | 20 | 75 | 21 |
| Nausea | 55 | 5 | 79 | 4 |
| Anemia | 50 | 30 | 42 | 29 |
| Neutrophil count decrease | 45 | 25 | 50 | 29 |
| Diarrhea | 30 | 0 | 33 | 4 |
| Constipation | 25 | 0 | 21 | 0 |
| Fatigue | 25 | 10 | 25 | 8 |
| Malaise | 20 | 0 | 38 | 0 |
| White-cell count decrease | 20 | 0 | 33 | 13 |
| Vomiting | 20 | 0 | 29 | 0 |
| Weight decrease | 20 | 0 | 29 | 8 |
| Peripheral edema | 20 | 0 | 4 | 0 |
| Dysgeusia | 20 | 0 | 4 | 0 |
| Pyrexia | 15 | 0 | 25 | 0 |
| Platelet count decrease | 15 | 0 | 29 | 13 |
| Hypoalbuminemia | 10 | 0 | 21 | 8 |

All hematologic terms are grouped terms. Febrile neutropenia occurred in 1 patient (cohort 1, grade 3).

| TEAEs Associated With: | Cohort 1 IHC 2+/ISH− (n = 20) | Cohort 2 IHC 1+ (n = 24) |
|---|---|---|
| Drug discontinuation, % | 10 | 4 |
| Dose reduction, % | 30 | 33 |
| Dose interruption, % | 40 | 42 |

- There were no drug-related deaths in either cohort
- Median treatment duration was 4.2 months (range, 1.3-10.5 months) in cohort 1 and 2.8 months (range, 0.7-14.9 months) in cohort 2
- One patient in each cohort had T-DXd–related ILD/pneumonitis (cohort 1, grade 1; cohort 2, grade 2) as determined by an independent adjudication committee
  - Time to onset was 248 days in cohort 1 and 171 days in cohort 2
  - At data cutoff, the case in cohort 2 was resolving and the case in cohort 1 had not resolved

# Conclusions
## DESTINY-Gastric Exploratory Cohort

- T-DXd demonstrated antitumor activity in patients with HER2-low gastric or GEJ adenocarcinoma
  - Cohort 1 (IHC 2+/ISH−): confirmed ORR, 26.3%; median OS, 7.8 months; median PFS, 4.4 months
  - Cohort 2 (IHC 1+): confirmed ORR, 9.5%; median OS, 8.5 months; median PFS, 2.8 months
- The safety profile of T-DXd was generally manageable and consistent with that in previous studies[1-4] and with the DESTINY-Gastric01 primary cohort[5]
  - The most common AEs were gastrointestinal or hematologic in nature
  - Signs and symptoms of ILD, a known risk with T-DXd, were actively monitored and managed with dose modification or discontinuation, corticosteroids, and supportive care in accordance with the study protocol
    - One case was reported in cohort 1 (grade 1) and 1 case in cohort 2 (grade 2)
- These findings provide preliminary evidence that T-DXd has clinical activity in patients with previously treated, HER2-low (IHC 2+/ISH−, IHC 1+) gastric or GEJ adenocarcinoma

1. Shitara K, et al. *Lancet Oncol.* 2019;20:827-836. 2. Modi S, et al. *N Engl J Med.* 2020;382:610-621. 3. Modi S, et al. *J Clin Oncol.* 2020;38:1887-1896. 4. Tsurutani J, et al. *Cancer Discov*. 2020;10:688-701.
5. Shitara K, et al. *N Engl J Med*. 2020;382:2419-2430.

# DXd-ADC Pipeline

As of September 2020

Daiichi-Sankyo

| Project (Target) | Target Indications | Discovery | Pre-clinical | Phase 1 | Phase2/3/Pivotal | Approve |
|---|---|---|---|---|---|---|
| DS-8201 (HER2) | Breast, gastric, NSCLC, CRC | | | | | |
| DS-1062 (TROP2) | NSCLC, breast | | | | | |
| U3-1402 (HER3) | Breast, NSCLC, CRC | | | | | |
| DS-7300 (B7-H3) | Solid tumor | | | | | |
| DS-6157 (GPR20) | GIST | | | | | |
| DS-6000 (undisclosed) | Renal, ovarian | | | | | |
| DS-3939 (TA-MUC1) | Solid tumor | | | | | |

: In clinical stage

# Q&A



## Contact address regarding this material

**Daiichi Sankyo Co., Ltd.**

**Corporate Communications Department**

**TEL: +81-3-6225-1126**

**Email:** DaiichiSankyoIR@daiichisankyo.co.jp